Back HCV Treatment

FDA Will Consider Approval of Daclatasvir for Genotype 3 Hepatitis C Treatment

The U.S. Food and Drug Administration (FDA) has accepted Bristol-Myers Squibb's application for approval of stand-alone daclatasvir (Daklinza) for the treatment of genotype 3 hepatitis C virus (HCV), to be used in combination with sofosbuvir (Sovaldi), the company announced last week.


Read more: